Many progresses for the treatment of multiple myeloma have been made since last decade.The application of novel target agents has brought the treatment of multiple myeloma into a new era.The outcomes of multiple myeloma have also been greatly improved with mechanism-based combinations of various agents.It is emphasized that clinicians should better understand the biological characteristics of myeloma cells and the anti-myeloma mechanisms underlined.In this review,the author will review the current status and make a prospective discussion in this field.

In present study,we detected HLA-DR antigens on monocytes of 28 patients with mutiplemyelomas (MM) and 20 normal controls with indirect immunofluorescent staining and flow cy-tometric technique.It was descovered that HLA-DR~+ monocytes of patients (33.63?16.24%)were greatly lower than these of normal controls (61.45?10.1% ) (P

Diagnostic Imaging ; Humans ; Multiple Myeloma ; diagnosis ; therapy

Humans ; Multiple Myeloma ; Neoplasm Recurrence, Local

Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Myeloma ; pathology ; therapy ; Neoplasm Staging ; Transplantation, Autologous

Multiple myeloma (MM) is one of hot topics in the 54th ASH annual meeting.There were over 700 myeloma related abstracts in 2012.The abstracts reflected recent progress of MM researches and fell into 4 major groups,including new drug trials,frontline options,biology and molecular genetics,and myelodysplastic syndrome prior to the onset of myeloma and myeloma treatment.

Multiple myeloma (MM) is a genetically complex disease that is becoming more common in today' s aging population.In the 18th European Hematology Association (EHA) annual meeting,there were a number of key topics focusing on the development of MM from intraclonal heterogeneity,novel therapeutic agents,and relapse and refractory MM therapy,etc.

Multiple myeloma is a malignancy of plasma cells,which is still incurable now.Despite dramatic improvement of the response rate and overall survival have been made due to the application of target therapy and stem cell transplantation,the treatment effect is difficult to maintain,nearly all patients will eventually relapse and become refractory.At relapse,the challenge is to select the appropriate treatment for each patient.The decision will be both disease-dependent and patient-dependent.

Multiple myeloma is the second most common hematological malignancy.In the 19th European Hematology Association (EHA) conference,there are a number of hot and key topics focused on developing of MM diagnosis criteria,response evaluation,treatment strategy for elderly and relapse/refractory myeloma patients,and maintenance therapy etc.

Objective To investigate the clinical efficacy of warm needling moxibustion in treating peptic ulcer.Methods Sixty patients with peptic ulcer were randomly allocated to treatment and control groups, 30 cases each. The treatment group received warm needling moxibustion and the control group took omeprazole and ranitidine. The clinical therapeutic effects were compared between the two groups after two months of treatment.Results The cure rate and the total efficacy rate were 53.3% and 93.3%, respectively, in the treatment group and 33.3% and 76.7%, respectively, in the control group; there were statistically significant differences between the two groups (P<0.05). The efficacy rates for symptoms (gastralgia, stomach fullness, belching and acid regurgitation, and nausea and vomiting) were 93.3%, 89.3%, 88.5% and 91.7%.Conclusion Warm needling moxibustion is an effective way to treat peptic ulcer.